Childhood Immunization Status (NQF 0038)
|
|
- Reginald Barrett
- 5 years ago
- Views:
Transcription
1 Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December 31, 20xx Measure Steward Natinal Cmmittee fr Quality Assurance Endrsed by Natinal Quality Frum Descriptin The percentage f children 2 years f age wh had fur diphtheria, tetanus and acellular pertussis (DTaP); three pli (IPV); ne measles, mumps and rubella (MMR); tw H influenza type B (HiB); three hepatitis B (Hep B), ne chicken px (VZV); fur pneumcccal cnjugate (PCV); tw hepatitis A (Hep A); tw r three rtavirus (RV); and tw influenza (flu) vaccines by their secnd birthday. The measure calculates a rate fr each vaccine and tw separate cmbinatin rates. Measure scring Prprtin Measure type Prcess Ratinale This measure mnitrs the apprpriate and timely use f vaccines fr children prir t their secnd birthday. Pediatric vaccines are respnsible fr preventing 10.5 millin diseases per birth chrt in the U.S. and are a cst effective preventive measure. Fr every dllar spent n immunizatins, as many as $29 can be saved in direct and indirect csts. With the develpment and use f vaccines, the prevalence f sme infectius diseases has dramatically reduced; since the beginning f the 20th century, there has been a 99% decline in vaccinepreventable disease mrbidity. Despite the established guidelines and well knwn benefits f vaccinatin, hwever, in 2007, 22.5% f children mnths f age had nt received the recmmended immunizatins. General clinical cnsensus ntes that if immunizatin practices ceased, mst infectius diseases currently prevented by vaccinatins wuld reemerge as serius health threats. This measure facilitates effrts tward infectius disease preventin amng a vulnerable subgrup f the ppulatin. Clinical Recmmendatin Statement Current CDC/ACIP Guidelines recmmend infants and tddlers receive the Hepatitis B series, fur DTaP vaccinatins, fur HiB vaccinatins, three IPV vaccinatins, ne MMR vaccinatin, fur pneumcccal cnjugate vaccinatins, and ne varicella vaccinatin. Sme cmbinatin prducts n the market include bth the DTaP and HiB vaccines and shuld nly be administered three times. In these cases, children receive three HiB vaccinatins instead f the fur mentined abve. The recmmendatin is t receive these vaccinatins between birth and 18 mnths f age. The current HEDIS specificatins allw a grace perid by measuring cmpliance with these recmmendatins between birth and age tw.
2 Reference Definitins CDC. General Recmmendatins n Immunizatin: Recmmendatins f the Advisry Cmmittee n Immunizatin Practices (ACIP). MMWR 2006; 55(RR15); Table f Cntents Ppulatin criteria Data criteria (QDS Data Elements) Summary calculatin Ppulatin criteria Initial Patient Ppulatin = AND: Patient characteristic: birth date (age) >=1 year and <2 years t capture all patients wh will reach 2 years during the measurement perid ; Denminatr = AND: All patients in the initial patient ppulatin; AND: Encunter: encunter utpatient w/pcp & bgyn ; Numeratr 1= AND: >= 4 cunt(s) f Medicatin administered: DTaP vaccine, different dates, ccurring >=42 OR: Medicatin allergy: DTaP vaccine ; OR: Diagnsis active: encephalpathy ; OR: Diagnsis active: prgressive neurlgical disrder ; Numeratr 2 = Numeratr 3 = AND: >=3 cunt(s) f Medicatin administered: IPV, different dates, ccurring >=42 OR: Medicatin allergy: IPV ; OR: Medicatin allergy: nemycin ; OR:: Medicatin allergy: streptmycin ; OR: Medicatin allergy: plymyxin ;
3 AND: Medicatin administered: MMR >=1, ccurring <2 years after the Patient OR: AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: > 1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: measles ; AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: mumps ; AND: >1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: rubella ; AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: >1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: MMR ; OR: Diagnsis active: immundeficiency ;
4 Numeratr 4 = Numeratr 5 = Numeratr 6 = AND: >=2 cunt(s) f Medicatin administered: HiB, ccurring >=42 days and <2 years after Patient Medicatin allergy: HiB ; AND: OR: >=3 cunt(s) f Medicatin administered: hepatitis B vaccine, ccurring < 2 years after Patient OR: Diagnsis reslved: hepatitis B diagnsis ; OR: Substance allergy: Baker s yeast ; OR: Medicatin allergy: hepatitis B vaccine ; AND: >=1 cunt(s) f Medicatin administered: VZV, ccurring < 2 years after Patient OR: Diagnsis reslved: VZV ; AND NOT OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: VZV ; OR: Diagnsis active: immundeficiency ; Numeratr 7 = Numeratr 8 = AND: >=4 cunt(s) f Medicatin administered: pneumcccal vaccine, ccurring >=42 Medicatin allergy: pneumcccal vaccinatin ; AND: >=2 cunt(s) f Medicatin administered: hepatitis A vaccine, ccurring <2 years after Patient OR: Diagnsis reslved: hepatitis A diagnsis ; AND NOT: Medicatin allergy: hepatitis A vaccine ; Numeratr 9 = AND: >=2 cunt(s) f Medicatin administered: rtavirus vaccine, ccurring >=42 days and <2 years after Patient Medicatin allergy: rtavirus vaccine ;
5 Numeratr 10 = Numeratr 11 = AND: >=2 cunt(s) f Medicatin administered: influenza vaccine, ccurring >=180 OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: influenza vaccine ; OR: Diagnsis active: immundeficiency ; AND: >= 4 cunt(s) f Medicatin administered: DTaP vaccine, different dates, ccurring >=42 OR: Medicatin allergy: DTaP vaccine ; OR: Diagnsis active: encephalpathy ; OR: Diagnsis active: prgressive neurlgical disrder ; AND: >=3 cunt(s) f Medicatin administered: IPV, different dates, ccurring >=42 OR: Medicatin allergy: IPV ; OR: Medicatin allergy: nemycin ; OR:: Medicatin allergy: streptmycin ; AND: Medicatin administered: MMR >=1, ccurring <2 years after the Patient OR: AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: > 1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: measles ; AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ;
6 AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: mumps ; AND: >1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: rubella ; AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: >1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: MMR ; OR: Diagnsis active: immundeficiency ; OR: Medicatin allergy: plymyxin ; AND: >=1 cunt(s) f Medicatin administered: VZV, ccurring < 2 years after Patient OR: Diagnsis reslved: VZV ; AND NOT OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: VZV ; OR: Diagnsis active: immundeficiency ; AND: OR: >=3 cunt(s) f Medicatin administered: hepatitis B vaccine, ccurring < 2 years after Patient
7 OR: Diagnsis active: hepatitis B diagnsis ; OR: Diagnsis reslved: hepatitis B diagnsis ; OR: Substance allergy: Baker s yeast ; OR: Medicatin allergy: hepatitis B vaccine ; Numeratr 12 = AND: >= 4 cunt(s) f Medicatin administered: DTaP vaccine, different dates, ccurring >=42 OR: Medicatin allergy: DTaP vaccine ; OR: Diagnsis active: encephalpathy ; OR: Diagnsis active: prgressive neurlgical disrder ; AND: >=3 cunt(s) f Medicatin administered: IPV, different dates, ccurring >=42 OR: Medicatin allergy: IPV ; OR: Medicatin allergy: nemycin ; OR:: Medicatin allergy: streptmycin ; AND: Medicatin administered: MMR >=1, ccurring <2 years after the Patient OR: AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: > 1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: measles ; AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: mumps ; AND: >1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient
8 Medicatin allergy: measles vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: rubella ; AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: >1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: MMR ; OR: Diagnsis active: immundeficiency ; OR: Medicatin allergy: plymyxin ; AND: >=1 cunt(s) f Medicatin administered: VZV, ccurring < 2 years after Patient OR: Diagnsis reslved: VZV ; AND NOT OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: VZV ; OR: Diagnsis active: immundeficiency ; AND: OR: >=3 cunt(s) f Medicatin administered: hepatitis B vaccine, ccurring < 2 years after Patient OR: Diagnsis reslved: hepatitis B diagnsis ; OR: Substance allergy: Baker s yeast ; OR: Medicatin allergy: hepatitis B vaccine ; AND: >=4 cunt(s) f Medicatin administered: pneumcccal vaccine, ccurring >=42 Medicatin allergy: pneumcccal vaccinatin ;
9 Exclusins = AND: Nne; Data criteria (QDS Data Elements) Initial Patient Ppulatin = "Patient characteristic: Birth date using birth date cde list befre the beginning f the measurement perid ; Denminatr = All patients in the initial patient ppulatin; Encunter: encunter utpatient w/pcp & bgyn using encunter utpatient w/pcp & bgyn cde list befre r simultaneusly t Numeratr = Medicatin allergy: DTaP using DTaP cde list befre r simultaneusly t the Medicatin allergy: nemycin using nemycin cde list befre measurement end Medicatin allergy: streptmycin using streptmycin cde list befre measurement end Medicatin allergy: plymyxin using plymyxin cde list befre measurement end Diagnsis active: encephalpathy using encephalpathy cde list gruping befre measurement end Diagnsis active: prgressive neurlgical disrder using prgressive neurlgical disrder befre measurement end Diagnsis active: cancer f lymphreticular r histicytic tissue using cancer f lymphreticular r histicytic tissue cde list gruping befre measurement end Diagnsis inactive: cancer f lymphreticular r histicytic disease using cancer f lymphreticular r histicytic tissue cde list gruping befre measurement end Diagnsis active: asymptmatic HIV using asymptmatic HIV cde list gruping befre measurement end Diagnsis active: multiple myelma using multiple myelma cde list gruping befre measurement end Diagnsis active: leukemia using leukemia cde list gruping befre measurement end Medicatin allergy: MMR using MMR cde list <=2 years befre measurement end Medicatin allergy: mumps vaccine using mumps vaccine cde list befre
10 Medicatin allergy: measles vaccine using measles vaccine cde list befre Medicatin allergy: VZV vaccine using VZV vaccine cde list befre measurement end Medicatin allergy: influenza vaccine using influenza vaccine cde list befre Substance allergy: Baker s yeast using Baker s yeast cde list befre measurement end Medicatin allergy: hepatitis B vaccine using hepatitis B vaccine cde list befre Medicatin allergy: hepatitis A vaccine using hepatitis A vaccine cde list befre Diagnsis reslved: hepatitis A diagnsis using hepatitis A diagnsis gruping cde list befre Medicatin allergy: rtavirus vaccine using rtavirus vaccine cde list befre Medicatin allergy: pneumcccal vaccine using pneumcccal vaccine cde list befre Medicatin allergy: HiB using HiB cde list befre Medicatin administered: DTaP using DTaP cde list befre the measurement end Medicatin administered: IPV using IPV cde list befre the measurement end Diagnsis reslved: measles using measles cde list gruping befre measurement end Diagnsis reslved: mumps using mumps cde list gruping befre measurement end Diagnsis reslved: rubella using rubella cde list gruping befre measurement end "Medicatin administered: MMR using MMR cde list befre the measurement end Medicatin administered: mumps vaccine using mumps vaccine cde list befre the Medicatin administered: measles vaccine using measles vaccine cde list befre the Medicatin administered: rubella vaccine using rubella vaccine cde list befre the "Medicatin administered: HiB using HiB cde list befre the measurement end Medicatin administered: hepatitis B vaccine using hepatitis B vaccine cde list befre the Diagnsis reslved: VZV using VZV cde list gruping befre the measurement end "Medicatin administered: VZV using VZV cde list befre the measurement end Medicatin administered: influenza vaccine using influenza vaccine cde list befre Diagnsis reslved: hepatitis B diagnsis using hepatitis B cde list gruping ;
11 Diagnsis active: hepatitis B diagnsis using hepatitis B cde list gruping ; "Medicatin administered: hepatitis A vaccine using hepatitis A vaccine cde list befre Medicatin administered: rtavirus vaccine using rtavirus vaccine cde list befre "Medicatin administered: pneumcccal vaccine using pneumcccal vaccine cde list befre Diagnsis active: immundeficiency using immundeficiency cde list gruping befre r simultaneusly t Exclusins = Nne; Summary calculatin Calculatin is generic t all measures: Calculate the final denminatr by adding all that meet denminatr criteria. Subtract frm the final denminatr all that d nt meet numeratr criteria yet als meet exclusin criteria. Nte sme measures d nt have exclusin criteria. The perfrmance calculatin is the number meeting numeratr criteria divided by the final denminatr. Fr measures with multiple patient ppulatins, repeat this prcess fr each patient ppulatin and reprt each result separately. Fr measures with multiple numeratrs, calculate each numeratr separately within each ppulatin using the paired exclusin. Measure set CLINICAL QUALITY MEASURE SET
Childhood Immunization Status (NQF 0038)
Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December
More informationDiabetes: HbA1c Poor Control (NQF 0059)
Diabetes: HbA1c Pr Cntrl (NQF 0059) EMeasure Name Diabetes: HbA1c Pr Cntrl EMeasure Id Pending Versin Number 1 Set Id Pending Available Date N infrmatin Measurement January 1, 20xx thrugh Perid December
More informationHeart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or
Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): Angitensin
More informationHeart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or
Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): EMeasure
More informationWeight Assessment and Counseling for Children and Adolescents (NQF 0024)
Weight Assessment and Cunseling fr Children and Adlescents (NQF 0024) EMeasure Name Weight Assessment and EMeasure Id Pending Cunseling fr Children and Adlescents Versin Number 1 Set Id Pending Available
More informationCoronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)
Crnary Artery Disease (CAD): Beta Blcker Therapy fr CAD Patients with Prir Mycardial Infarctin (MI) (NQF 0070) EMeasure Name Crnary Artery Disease EMeasure Id Pending (CAD): Beta Blcker Therapy fr CAD
More informationPediatric and adolescent preventive care and HEDIS *
Pediatric and adlescent preventive care and HEDIS * * HEDIS is a registered trademark f the Natinal Cmmittee fr Quality Assurance (NCQA). UniCare Health Plan f West Virginia, Inc. Healthcare Effectiveness
More informationVaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE
Vaccine Infrmatin Statement: PNEUMOCOCCAL CONJUGATE VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationDiphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)
Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Pli-Haemphilus Influenzae type b Cnjugate Cmbined Vaccine Bilgical Page (DTaP-IPV-Hib-HB) Sectin 7: Bilgical Prduct Infrmatin Standard #: 07.214 Created
More informationDiphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)
Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Pli-Haemphilus Influenzae type b Cnjugate Cmbined Vaccine Bilgical Page (DTaP-IPV-Hib-HB) Sectin 7: Bilgical Prduct Infrmatin Standard #: 07.214 Created
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationMedical Student Immunization Requirements
Medical Student Immunizatin Requirements The State f Illinis cde, Reference: (110 ILCS 20) Cllege Student Immunizatin Act, requires students t prvide prf f immunity: Measles (Rubela), Mumps, Rubella (German
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationChildhood Immunization Status
emeasure Title emeasure Identifier (Measure Authoring Tool) Childhood Immunization Status 117 emeasure Version number 5.1.000 NQF Number 0038 GUID b2802b7a-3580-4be8-9458- 921aea62b78c Measurement Period
More informationDear Student, IMMUNIZATION RECORD INSTRUCTIONS
Dear Student, Welcme t the University f Chicag! The State f Illinis and University regulatins require students t prvide prf f required immunizatins prir t registratin fr classes. In rder t cmplete this
More informationCDC Influenza Technical Key Points February 15, 2018
CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity
More informationHigh Performance Network Quality Criteria for Designation
Selected quality measures include: Specialty Measure Descriptin Allergy / Immunlgy Asthma Drug Mgt Vaccine Pneumnia Vaccine High Perfrmance Netwrk Quality Criteria fr Designatin AvMed has selected certain
More informationDear University of Chicago Student,
Dear University f Chicag Student, The state f Illinis and the University f Chicag require students t have prf f immunity fr certain diseases including Measles (Rubela), Mumps, Rubella (German Measles)
More informationPATH Quick Reference Guide: Coding for Pediatric Health HEDIS Measures
PATH Quick Reference Guide: Coding for Pediatric Health HEDIS Measures This guide is designed to be a quick reference tool to help with medical coding of select Healthcare Effectiveness Data and Information
More information2017 CMS Web Interface
CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationIowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training
Iwa Early Peridic Screening, Diagnsis and Treatment Care fr Kids Prgram Prvider Training The Early Peridic Screening, Diagnsis and Treatment (EPSDT) Care fr Kids prgram is Iwa s Medicaid prgram fr children.
More informationSafety of HPV vaccination: A FIGO STATEMENT
FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have
More informationLTCH QUALITY REPORTING PROGRAM
4 LTCH QUALITY REPORTING PROGRAM GENERAL INFORMATION...3 LTCH FACILITY-LEVEL QUALITY MEASURE REPORT...5 LTCH PATIENT-LEVEL QUALITY MEASURE REPORT...18 LTCH REVIEW AND CORRECT REPORT...23 09/2018 v1.04
More informationImmunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years)
Immunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years) Guideline developed by Shelly Baldwin, MD, in collaboration with the ANGELS Team. Last reviewed by Shelly Baldwin,
More information2018 CMS Web Interface
CMS Web Interface HTN-2 (NQF 0018): Cntrlling High Bld Pressure Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 18 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE SAMPLING INFORMATION... 4
More informationMEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache
MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache Measure Descriptin All patients diagnsed with migraine headache r cervicgenic headache wh had a headache management
More information2018 CMS Web Interface
CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.1 Page 1 f 27 06/25/ Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...
More information2018 CMS Web Interface
CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.0 Page 1 f 27 11/13/2017 Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...
More information2018 CMS Web Interface
CMS Web Interface IVD-2 (NQF 0068): Ischemic Vascular Disease (IVD): Use f Aspirin r Anther Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 20 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE
More informationCHILDHOOD IMMUNIZATIONS
CHILDHOOD IMMUNIZATIONS APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE What immunizations should be administered? NCQA ACCEPTED CODES DOCUMENTATION
More information2017 CMS Web Interface
CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF 0055): Diabetes: Eye Exam Measure Steward: NCQA Web Interface
More information2017 CMS Web Interface
CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...
More informationMeasure Information Form
Release Ntes: Measure Infrmatin Frm Versin 2.0 **NQF-ENDORSED VOLUNTRY CONSENSUS STNDRDS FOR HOSPITL CRE** Measure Set: Heart Failure (HF) Set Measure ID#: Measure Infrmatin Frm Perfrmance Measure Name:
More information2018 CMS Web Interface
CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF Measure Steward: NCQA CMS Web Interface V2.1 Page 1 f 26
More informationHealthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.
Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy
More informationHEDIS. Healthcare Effectiveness Data & Information Set (HEDIS ) QUALITY MANAGEMENT PROGRAM SECTION 8
HEDIS Healthcare Effectiveness Data & Infrmatin Set (HEDIS ) The HEDIS â audit cntains a cre set f perfrmance measures that prvide infrmatin abut custmer satisfactin, specific health care measures, and
More informationThe data refer to persons aged between 15 and 54.
Drug-related hspital stays in Australia 1993-2005 Prepared by Amanda Rxburgh and Luisa Degenhardt, Natinal Drug and Alchl Research Centre Funded by the Australian Gvernment Department f Health and Ageing
More informationCDC Influenza Division Key Points MMWR Updates February 20, 2014
CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February
More informationImmunisation and Disease Prevention Policy
Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries
More informationAppendix An Assessment Tool to Determine the Validity of Vaccine Doses
Appendix 4.4 - An Assessment Tool to Determine the Validity of Vaccine Doses Note: Refer to the Canadian Immunization Guide and New Brunswick (NB) immunization program directives for recommendations for
More informationVaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE
Vaccine Infrmatin Statement: LIVE INTRANASAL INFLUENZA VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationOsteoporosis Fast Facts
Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased
More information2018 CMS Web Interface
PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS CMS
More informationMichigan Primary Care Transformation Project Performance Incentive Technical Manual
Michigan Primary Care Transfrmatin Prject 2016 Perfrmance Incentive Technical Manual Fr Physician Organizatins, Physician Hspital Organizatins, Independent Practice Assciatins and Primary Care Practices
More information2017 CMS Web Interface
CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening and Fllw- Measure Steward: CMS Web Interface V1.0 Page 1 f 23 11/15/2016 Cntents INTRODUCTION... 3 WEB
More informationConsensus Recommendations for the Management of Chronic Lymphocytic Leukemia: Primary Care Guideline
Practice Guideline: Clinical Guide Cnsensus Recmmendatins fr the Management f Chrnic Lymphcytic Leukemia: Primary Care Guideline CCMB Practice Guideline Clinical Guide Develped by: Lymphprliferative Disrders
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationProof of residency in East Orange is mandatory (see Residency Requirements)
Pre-K Registration Requirements Child must be at least 3 or 4 years old by October 1st of the current school year Immunization (shot records) are mandatory Age appropriate vaccinations for children entering
More informationRequest for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax
Request fr Prir Authrizatin fr Click here t enter text. Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 Updated: 05/2018 DMMA Apprved: 05/2018 All requests fr Intravenus
More informationResponse to. type 2 vaccine-derived polioviruses. prior to global topv withdrawal. Interim Guidelines
Respnse t type 2 vaccine-derived pliviruses prir t glbal topv withdrawal Interim Guidelines August 2015 GPEI peratinal guidance nte August 2015 Summary Prepare fr prmpt actin fr any area r ppulatin at
More information2017 CMS Web Interface
CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS Web Interface V1.1 Page 1 f 27 12/15/2016 Cntents INTRODUCTION... 4 WEB INTERFACE SAMPLING
More information2018 CMS Web Interface
CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 27 06/25/ Cntents INTRODUCTION... 4 CMS WEB INTERFACE
More informationSECTION O. MEDICATIONS
SECTION O. MEDICATIONS 1. NUMBER OF MEDICA TIONS (Recrd the number f different medicatins used in the last 7 days; enter "0" if nne used) O1. Number f Medicatins (7-day lk back) Intent: Prcess: Cding:
More informationWhat DO the childhood immunization footnotes reveal? Questions and answers
What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination
More informationDiphtheria-Tetanus-Acellular Pertussis Combined Vaccine Biological Page (dtap)
Diphtheria-Tetanus-Acellular Pertussis Cmbined Vaccine Bilgical Page (dtap) Sectin 7: Bilgical Prduct Infrmatin Standard #: 07.210 Created by: Apprved by: Prvince-wide Immunizatin Prgram Standards and
More informationQuest for Quality: Immunizations
Quest for Quality: Immunizations DANE COUNTY IMMUNIZATION COALITION MEMBERSHIP MEETING November 13, 2012 Elaine Rosenblatt MSN, FNP-BC Director, Quality and Care Management UW Medical Foundation/ Unity
More information2018 CMS Web Interface
CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 24 06/25/ Cntents INTRODUCTION... 3 CMS WEB INTERFACE
More informationFlu Season Key Points ( )
2014-2015 Flu Seasn Key Pints (10-31-14) Cntents Overarching Framewrk f CDC Influenza Messaging... 3 Take 3 Messages... 3 Statements fr General Audiences... 4 Disease... 4 Vaccinatin... 6 Vaccinatin Timing...
More information2018 CMS Web Interface
CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 23 06/25/ Cntents INTRODUCTION... 3 CMS WEB INTERFACE
More information2016 Cross-Cutting Measure Set
1 0059 Diabetes: Hemoglobin A1c Poor Control: Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the 46 0097 Claims, Registry Medication Reconciliation Post Discharge:
More informationProvider Information: Influenza VISs
Prvider Infrmatin: Influenza VISs Thirteen influenza vaccine prducts are apprved fr use in the United States fr the 2014-15 influenza seasn: Name Manufacturer Age Range # f Strains Afluria bicsl 9 years
More information2017 CMS Web Interface
CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Fllw-Up Measure Steward: CMS Web Interface V1.0 Page 1 f 22 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. The United States is currently experiencing a natinwide utbreak f entervirus D68 (EV-D68) assciated with severe
More informationThe estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by
ESTIMATION PROCEDURES USED TO PRODUCE WEEKLY FLU STATISTICS FROM THE HEALTH INTERVIEW SURVEY James T. Massey, Gail S. Pe, Walt R. Simmns Natinal Center fr Health Statistics. INTRODUCTION In April 97, the
More informationRecommended Health Screenings
Recommended Health Screenings UnitedHealthcare appreciates the preventive care you deliver to our members. Please use the below health screening chart to schedule screenings based on the member s age and
More informationChapter 6: Impact Indicators
Overview Chapter 6: Impact Indicatrs The best measure f the lng-term impact f all HIV preventin activities is the HIV incidence rate, namely the number f new cases f HIV infectin per year divided by the
More informationCDC Influenza Division Key Points November 7, 2014
In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates
More informationStrep Test 87070, 87071, 87081, Pharyngitis (CWP)
Clinical Excellence Measures Use of these codes should be appropriate to the service(s) rendered and follow the billing guidelines. For HEDIS measures the codes are from the NCQA HEDIS specifications and
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationImmunizations are among the most cost effective and widely used public health interventions.
Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More informationRECOMMENDED IMMUNIZATIONS
Recommended Immunization Schedule for Persons Aged 0 Through 6 Years United States 2010 1 2 4 6 12 15 18 19 23 2 3 4 6 Vaccine Age Birth month months months months months months months months years years
More informationThis information shows what new challenges are likely to require prevention efforts moving forward.
Release f CDC s Healthcare-Assciated Infectins (HAI) Pint Prevalence Survey and Annual Natinal and State HAI Prgress Reprt Embarged until: Wednesday, March 26 th at 12 nn ET Key Messages Overall These
More informationQUALITY AND SAFETY MEASURES UPDATE January 2016
CLINICAL EFFECTIVENESS/SAFETY M CORE MEASURES 2015 See attached Results QUALITY AND SAFETY MEASURES UPDATE January 2016 Jint Cmmissin and CMS Cre Measure Dashbard updated with mst recent data available:
More informationMedicare Advantage 2019 Advance Notice Part 1 21 st Century Cures Act Methodological Changes
Medicare Advantage 2019 Advance Ntice Part 1 21 st Century Cures Act Methdlgical Changes Review f Relevant Prvisins with Expert Insight January 2018 PULSE8 is privileged t bring yu a summary f key Medicare
More informationPediatric Quality Measure Information Sheet 2017
Prevention and Screening Adolescent Preventive Care Measures (APC) The percentage of adolescents 12-17 years of age who had at least one outpatient visit with a PCP or OB/ GYN practitioner during the measurement
More information2018 CMS Web Interface
CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening Measure Steward: CMS CMS Web Interface V2.0 Page 1 f 23 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE
More informationChild and Adult Preventive Care Services
Child and Adult Preventive Care Services Adult and Child Preventive Care Services will meet the requirements as determined by federal and state law. Cvered preventive care services prvided by a Participating
More informationMeaningful Use Roadmap Stage Edition Eligible Hospitals
Meaningful Use Radmap Stage 1-2011 Editin Eligible Hspitals CPSI is dedicated t making yur transitin t Meaningful Use as seamless as pssible. Therefre, we have cme up with a radmap t assist yu in implementing
More informationCommunicable Disease & Immunization
Communicable Disease & Immunization Ingham County Health Surveillance Book 2016 Communicable Disease & Immunization - 1 Communicable Disease & Immunization T he control of communicable disease and immunization,
More informationSection V: Immunization
Michigan Lcal Public Health Accreditatin Prgram Tl 2014 MPR Indicatr Guide Sectin V: Immunizatin MPR 1 The lcal health department shall ffer immunizatin services t the public fllwing a cmprehensive plan
More informationImmunization Guidelines for the Use of State Supplied Vaccine April 18, 2013
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationContinuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator
Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results
More informationImmunization Guidelines For the Use of State Supplied Vaccine July 1, 2011
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More information46825 (260) $UPONT
Be wise. Immunize. Keeping track of the shots your children receive can be confusing. This is an important responsibility that is shared by you and your immunization providers. This booklet contains the
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. Over the last several mnths, the United States has experienced a natinwide utbreak f entervirus D68 (EV- D68) assciated
More informationPennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain
Pennsylvania Guidelines n the Use f Opiids t Treat Chrnic Nncancer Pain Chrnic pain is a majr health prblem in the United States, ccurring with a pintprevalence f abut ne-third f the US ppulatin.(1) Mre
More informationUNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES.
Initial privileges (initial appintment) Renewal f privileges (reappintment) Expansin f privileges (mdificatin) INSTRUCTIONS All new applicants must meet the fllwing requirements as apprved by the UNM SRMC
More information2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE
2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizatins, Clinical Cascade Breakut Sessin TB/HIV EXERCISE Created by the ICPI TB/HIV Wrkstream Abut this Handut
More informationNovel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states.
Nvel methds and appraches fr sensing, evaluating, mdulating and regulating md and emtinal states. 2018 Jy Academic Grant Call fr Prpsals Intrductin The Annual Jy grant initiative aims t prmte and cntribute
More informationPreventive care is important at every age. Making good health choices now can boost your health and well-being for a lifetime.
Adult Recommendations Preventive care is important at every age. Making good health choices now can boost your health and well-being for a lifetime. Asthma and COPD Well-Child Visits Children s Immunization
More informationInfluenza (Flu) Fact Sheet
Influenza (Flu) Fact Sheet What is the flu? The flu is a cntagius respiratry illness caused by influenza viruses. It can cause mild t severe illness, and at times can lead t death. Sme peple, such as lder
More informationUtah s Immunization Rule Individual Vaccine Requirements
Utah s Immunization Rule Individual Vaccine Requirements Which vaccines are required for school entry in Utah? Grades K-6: 5 doses DTaP (4 doses if the 4 th dose was given after the 4 th birthday) 4 doses
More informationSchool Nurse Regional Update School Year Immunizations COLORADO IMMUNIZATION BRANCH
School Nurse Regional Update 2017-18 School Year Immunizations COLORADO IMMUNIZATION BRANCH Talking Points Child Care Immunizations K through 12 th Grade Immunizations Official Medical and Non-Medical
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationReferral Criteria: Inflammation of the Spine Feb
Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationDATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS
DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this
More informationCommonwealth of Kentucky Department for Medicaid Services Division of Program Quality and Outcomes
Cmmnwealth f Kentucky Department fr Medicaid Services Divisin f Prgram Quality and Outcmes EPSDT Screening Encunter Data Validatin Clinical Fcused Study 2014 FINAL REPORT May 2014 TABLE OF CONTENTS INTRODUCTION...
More information